Skip to Main Content

An international tribunal sided against Eli Lilly in a closely watched claim that the drug maker brought against the Canadian government over its right to set patent laws.

The dispute centered on different Canadian court rulings several years ago that invalidated patents on two Lilly drugs. Those decisions prompted the arrival of cheaper generics on the Canadian market, which Lilly claims led to “significant” sales and job losses in Canada.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED